The supplement allows the company to expand patient enrollment in the REMIND investigational device exemption (IDE) study. MMI can now increase enrollment beyond the initial five-patient cohort to a full early feasibility study population of 15 patients. The company received the FDA’s go-ahead to conduct the study in November 2025.

REMIND evaluates microsurgical intervention for neurodegenerative disease, including Alzheimer’s disease. The first-of-its-kind trial evaluates the safety and feasibility of the Symani surgical robot in microsurgery in the region of the neck.